| Field | Specification |
|---|---|
| Mfr No | |
| Detection Method | |
| Product Type | |
| Sample Type(s) | Compounds that affect farnesyltransferase activity |
| Shipping | |
| Species | |
| Storage |
Overview
For high-throughput screening of FTase inhibitors and evaluation of drug modulators. The assay uses FL340/550 nm for signal readout. Compatible sample input includes Compounds that affect farnesyltransferase activity. Typical stated assay timing is 60 min.
Key elements and design rationale
- Readout format: FL340/550 nm supports plate-based signal acquisition and consistent comparison across matched samples.
- Sample compatibility: The stated sample scope includes Compounds that affect farnesyltransferase activity, which is useful when aligning matrix type with calibration and control design.
- Workflow timing: The listed assay time of 60 min helps frame batch planning, replicate handling, and plate throughput.
- Feature emphasis: Safe. Non-radioactive assay.
Additional feature notes highlight Homogeneous and convenient. “Mix-incubate-measure” type assay. No wash and reagent transfer steps are involved; High-throughput. A Z’-factor of 0.8 and higher is routinely observed in a 384-well format. Can be readily automated to assay thousands of samples per day. Available format information for this listing includes 400 Tests in 384-well plate (Custom bulk sizes available upon request).
Biological background
This product is centered on measurement of enzyfluo farnesyltransferase inhibitor screening within the matrices described for the assay. In practice, datasets from this type of format are typically interpreted by comparing relative signal, activity, or abundance across matched control and experimental groups rather than relying on a single value in isolation. Careful alignment of sample matrix, incubation window, and calibration strategy is important when comparing results across plates, operators, or study days.
More details
FARNESYLTRANSFERASE(FTase, EC 2.5.1.58) catalyzes the transfer of a farnesyl group from farnesyl pyrophosphate to the cysteine residue of the C-terminus of target proteins. When not properly regulated, farnesylated proteins, including the Ras superfamily of small GTPases, can lead to developmental disorders and cancer. Simple, direct and high-throughput inhibitor screening assays find wide applications for oncology research. BioAssay Systems’ EIFT-400 assay kit provides a convenient fluorimetric method to screen for potential FTase inhibitors. In this assay, FTase reacts with farnesyl pyrophosphate and a dansyl-peptide substrate with measurable fluorescence at λem/ex = 340/550 nm. Inhibition is determined by the decrease in fluorescence.
Detection method
Fluorescent (FL 340/550 nm).
Procedures and timing
Stated procedure or timing information: 60 min.
Screening services
BioAssay Systems offers comprehensive FTase lead discovery services, including compound library screening, inhibitor profiling, and high-throughput assays to identify potential drug candidates. We provide detailed analyses of compound activity, potency, and selectivity, supporting hit-to-lead and lead optimization efforts. Please contact us for more details at Service .
Research relevance and current trends
- Plate-based quantification and side-by-side group comparison remain central use cases for this assay format.
- The product notes emphasize multi-sample throughput, making it relevant for screening-oriented and larger batch comparison studies.
- The description supports intervention-focused study designs in which researchers compare baseline and perturbed conditions.
Common research applications
- Quantify enzyfluo farnesyltransferase inhibitor screening in compounds that affect farnesyltransferase by FL340/550 nm.
- Compare treatment or phenotype groups using matched compounds that affect farnesyltransferase handling.
- Monitor time-course or pre/post changes in compounds that affect farnesyltransferase across study conditions.
Interpretation is usually strongest when signal changes are assessed alongside matrix-matched controls, replicate agreement, and the assay's stated analytical window.
Notes for experimental interpretation
- Matrix composition, background signal, and sample handling can influence apparent response; compare like-with-like whenever possible.
- Use appropriate blanks, controls, and replicate wells to distinguish biological differences from plate, reagent, or handling variability.
I only have a spectrophotometer that reads OD. Would it be possible to run this assay colorimetrically?
One of the main substrates in this assay is a dansyl peptide fluorophore so the assay must be run fluorometrically
Does the kit include FTase enzyme?
This kit does not include enzyme. The purpose of this assay is to determine the FTase activity of the sample. If a pure enzyme is desired, the customer can purchase it from e.g Jena Biosciences, cat# PR-102.
For laboratories requiring additional technical capacity, we provide scientific support services including assay execution, method guidance, product sourcing, and customization to align the assay with specific experimental objectives. If you need assistance selecting the appropriate kit configuration, adapting the workflow to your application, or identifying related research services, please click Talk to a Scientist, email support@biohippo.com, or review our Research Services; a member of our scientific team will follow up with recommendations tailored to your study.
